Effects of single dose GnRH agonist as luteal support on pregnancy outcome in frozen-thawed embryo transfer cycles: an RCT

Davar, Robab; Mojtahedi, Maryam Farid; Miraj, Sepideh
August 2015
Iranian Journal of Reproductive Medicine;Aug2015, Vol. 13 Issue 8, p483
Academic Journal
Background: There is no doubt that luteal phase support is essential to enhance the reproductive outcome in IVF cycles. In addition to progesterone and human chorionic gonadotropin, several studies have described GnRH agonists as luteal phase support to improve implantation rate, pregnancy rate and live birth rate, whereas other studies showed dissimilar conclusions. All of these studies have been done in fresh IVF cycles. Objective: To determine whether an additional GnRH agonist administered at the time of implantation for luteal phase support in frozen-thawed embryo transfer (FET) improves the embryo developmental potential. Materials and Methods: This is a prospective controlled trial study in 200 FET cycles, patients were randomized on the day of embryo transfer into group 1 (n=100) to whom a single dose of GnRH agonist (0.1 mg triptorelin) was administered three days after transfer and group 2 (n=100), who did not receive agonist. Both groups received daily vaginal progesterone suppositories plus estradiol valerate 6 mg daily. Primary outcome measure was clinical pregnancy rate. Secondary outcome measures were implantation rate, chemical, ongoing pregnancy rate and abortion rate. Results: A total of 200 FET cycles were analyzed. Demographic data and embryo quality were comparable between two groups. No statistically significant difference in clinical and ongoing pregnancy rates was observed between the two groups (26% versus 21%, p=0.40 and 21% versus 17%, p=0.37, respectively). Conclusion: Administration of a subcutaneous GnRH agonist at the time of implantation does not increase clinical or ongoing pregnancy.


Related Articles

  • First live birth following IVF-embryo transfer and use of GnRHa alone for ovarian stimulation. Azem, Foad; Almog, Beni; Ben-Yosef, Dalit; Kapustiansky, Rita; Wagman, Israel; Amit, Ami // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Aug2009, Vol. 19 Issue 2, p162 

    Several case reports have shown that some patients may develop ovarian cysts or ovarian hyperstimulation syndrome following the administration of gonadotrophin-releasing hormone agonist (GnRHa). This is the first report of a live birth following ovarian stimulation and IVF-embryo transfer using...

  • Transfer of Cryopreserved-Thawed Embryos in a Cycle Using Exogenous Steriods with or Without Prior Gonadotropihin-Releasing Hormone Agonist. Davar, Robab; Eftekhar, Maryam; Tayebi, Naeimeh // Journal of Medical Sciences;2007, Vol. 7 Issue 5, p880 

    The aim of this study was to investigate the outcome of frozen-thawed embryo transfer in exogenous estrogen plus progesterone without GnRH agonist and with GnRH agonist cycles for endometrial preparation in women with regular menstrual cycles. This study was designed as a prospective randomized...

  • Elevated progesterone in GnRH agonist down regulated in vitro fertilisation (IVFICSI) cycles reduces live birth rates but not embryo quality. Lahoud, Robert; Kwik, Michele; Ryan, John; Al-Jefout, Moamar; Foley, Jane; Illingworth, Peter // Archives of Gynecology & Obstetrics;Feb2012, Vol. 285 Issue 2, p535 

    Objective: To assess the impact of pre-hCG elevated progesterone on live birth outcomes during GnRH agonist long down regulated protocol assisted reproduction cycles. Design: Retrospective cohort study. Setting: Single Centre Private IVF Clinic. Patients: A total of 582 consecutive cycles of...

  • Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger. Kummer, N.E.; Feinn, R.S.; Griffin, D.W.; Nulsen, J.C.; Benadiva, C.A.; Engmann, L.L. // Human Reproduction;Jan2013, Vol. 28 Issue 1, p152 

    STUDY QUESTION Are there factors predicting the number of total and mature oocytes retrieved after controlled ovarian hyperstimulation (COH) utilizing a gonadotropin-releasing hormone (GnRH) antagonist protocol and a GnRH agonist (GnRHa) to induce oocyte maturation? SUMMARY ANSWER Peak estradiol...

  • Comparing GnRH agonist long protocol and gnrh antagonist protocol in outcome the first cycle of ART. Firouzabadi, Razieh; Ahmadi, Shahnaz; Oskouian, Homa; Davar, Robab // Archives of Gynecology & Obstetrics;Jan2010, Vol. 281 Issue 1, p81 

    This prospective study evaluated the efficacy of gonadotropin-releasing hormone (GnRH) antagonist protocol in comparison with the GnRH agonist protocol in the first cycle of assisted reproductive technique (ART). We randomized 235 patients undergoing ART for the first time. The first group was...

  • Drop in reimbursement led to drop in inappropriate ADT use.  // PharmacoEconomics & Outcomes News;1/8/2011, Issue 619, p6 

    The article discusses research on the link between the use of androgen deprivation therapy (ADT) and reimbursement for gonadotropin releasing hormone (GnRH) agonists in the U.S., by V. B. Shahinian and colleagues, published in the "New England Journal of Medicine."

  • AHCPR: LHRH agonists are equally effective.  // Urology Times;Mar99, Vol. 27 Issue 3, p3 

    Cites an Agency for Health Policy Research report which said that luteinizing hormone-releasing agonists produce roughly the same survival and side effects in men with advanced prostate cancer, regardless of which of the testosterone-suppressing drugs is taken.

  • Towards healthier infertility. Judson, Olivia P. // Nature;9/2/1993, Vol. 365 Issue 6441, p15 

    Discusses the results of a two-year pilot trial on a contraceptive based on a gonadotropin-releasing hormone agonist. Reduction of the relative risk of breast cancer; Absence of premenstrual syndrome; Addition of oestrogen and progesterone pills to the regimen to avoid bone loss associated with...

  • Effect of GnRH Agonists on Implantation.  // Fertility Weekly;12/18/2006, p2 

    The article cites a study conducted by researchers from Spain which found that the use of gonadotropin-releasing hormone (GnRH) agonist for ovulation does not affect the rate of embryo implant. The study has evaluated the capacity of embryos derived from oocytes matured with bolus of GnRH...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics